Cyclin-Dependent Kinase 4/6 Inhibitor in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Global Challenges and Tibremciclib Perspective

Tibremciclib shows promise as an additional CDK4/6 inhibitor; however, its global integration requires broader, more diverse clinical trials, robust safety and survival data, and strategies to mitigate toxicity risks. Bridging access gaps will require coordinated efforts across policy, infrastructure, and global partnerships to ensure equitable benefit from emerging therapies.